Filtered By:
Condition: Diabetes
Drug: Zivast
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 47 results found since Jan 2013.
Kanglexin, a new anthraquinone compound, attenuates lipid accumulation by activating the AMPK/SREBP-2/PCSK9/LDLR signalling pathway.
In this study, Sprague-Dawley rats were fed a high fat diet (HFD) for 5 weeks to establish a hyperlipidaemia model; then, the rats were orally administered KLX (20, 40, and 80 mg kg-1·d-1) or atorvastatin calcium (AT, 10 mg kg-1·d-1) once a day for 2 weeks. KLX had prominent effects on reducing blood lipids, hepatic lipid accumulation, body weight and the ratio of liver weight/body weight. Furthermore, KLXdramatically reduced the total cholesterol (TC) and triglyceride (TG) levels and lipid accumulation in a HepG2 cell model of dyslipidaemia induced by 1 mmol/L oleic acid (OA). KLX may decrease lipid levels by phosphoryl...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - November 14, 2020 Category: Drugs & Pharmacology Authors: Li X, Hu X, Pan T, Dong L, Ding L, Wang Z, Song R, Wang X, Wang N, Zhang Y, Wang J, Yang B Tags: Biomed Pharmacother Source Type: research
Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at “Extreme” ASCVD Risk
AbstractPurpose of ReviewTo review randomized interventional clinical and imaging trials that support lower targeted atherogenic lipoprotein cholesterol goals in “extreme” and “very high” atherosclerotic cardiovascular disease (ASCVD) risk settings. Major atherosclerotic cardiovascular event (MACE) prevention among the highest risk patients with ASCVD requires aggressive management of global risks, including lowering of the fundamental atherogenic ap olipoprotein B-associated lipoprotein cholesterol particles [i.e., triglyceride-rich lipoprotein remnant cholesterol, low-density lipoprotein cholesterol (LDL-C), and ...
Source: Current Diabetes Reports - November 20, 2019 Category: Endocrinology Source Type: research
Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial
Publication date: Available online 9 August 2019Source: American Heart JournalAuthor(s): Kausik K. Ray, Stephen J. Nicholls, Henry Ginsberg, Jan O. Johansson, Kamyar Kalantar-Zadeh, Ewelina Kulikowski, Peter P. Toth, Norman Wong, Jeffrey L. Cummings, Michael Sweeney, Gregory G. SchwartzAbstractBackgroundAfter an acute coronary syndrome (ACS), patients with diabetes remain at high risk for additional cardiovascular events despite use of current therapies. Bromodomain and extra-terminal (BET) proteins are epigenetic modulators of inflammation, thrombogenesis, and lipoprotein metabolism implicated in atherothrombosis. The BET...
Source: American Heart Journal - August 9, 2019 Category: Cardiology Source Type: research
Effect of Intensive Blood Pressure Control on Carotid Morphology and Hemodynamics in Chinese Patients with Hyperhomocysteinemia-Type Hypertension and High Risk of Stroke.
CONCLUSIONS Intensive blood pressure management could be beneficial for Chinese patients with hyperhomocysteinemia-type hypertension and high risk of stroke.
PMID: 31369520 [PubMed - in process]
Source: Medical Science Monitor - August 3, 2019 Category: Research Tags: Med Sci Monit Source Type: research
A Multicenter, Randomized, Placebo ‐Controlled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis
ConclusionAtorvastatin 40 mg daily is safe and results in a significantly greater reduction of LDL cholesterol level than placebo in patients with RA. The 34% CVE risk reduction is consistent with the Cholesterol Treatment Trialists ’ Collaboration meta‐analysis of statin effects in other populations.
Source: Arthritis and Rheumatology - July 21, 2019 Category: Rheumatology Authors: George D. Kitas,
Peter Nightingale,
Jane Armitage,
Naveed Sattar,
Jill J. F. Belch,
Deborah P. M. Symmons, on behalf of
the TRACE RA Consortium,
George Kitas,
Jill Belch,
Deborah Symmons,
Hawys Williams,
Shobna Vasishta,
Rebecca Storey,
Pete Tags: Original Article Source Type: research
Patient-Associated Characteristics Influencing the Risk for Non-Persistence with Statins in Older Patients with Peripheral Arterial Disease
ConclusionsPatients identified as high risk for non-persistence require special attention aimed at the improvement of their persistence with statin treatment.
Source: Drugs and Aging - June 28, 2019 Category: Geriatrics Source Type: research
Preventable Cases of Oral Anticoagulant-Induced Bleeding: Data From the Spontaneous Reporting System
Conclusion: Our findings describe the most reported risk factors for preventability of oral anticoagulant-induced bleedings. These factors may be useful for targeting interventions to improve pharmacovigilance activities in our regional territory and to reduce the burden of medication errors and inappropriate prescription.
Introduction
Oral anticoagulant therapy is widely used for the prevention of stroke and systemic embolism in patients with atrial fibrillation, or for the prevention and treatment of deep vein thrombosis and pulmonary embolism (Raj et al., 1994; Monaco et al., 2017). Oral anticoagulants can be di...
Source: Frontiers in Pharmacology - April 29, 2019 Category: Drugs & Pharmacology Source Type: research
Trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis (TRACE RA): A multicenter, randomized, placebo controlled trial
ConclusionAtorvastatin 40mg daily was safe and resulted in significantly greater reduction of LDLc than placebo in patients with RA. The 40% (adjusted) CVE risk reduction is consistent with the Cholesterol Treatment Trialists ’ Collaboration meta‐analysis of statin effects in other populations.This article is protected by copyright. All rights reserved.
Source: Arthritis and Rheumatology - April 14, 2019 Category: Rheumatology Authors: George D. Kitas,
Peter Nightingale,
Jane Armitage,
Naveed Sattar,
Jill J.F. Belch,
Deborah P.M. Symmons,
The TRACE RA consortium,
George Kitas,
Jill Belch,
Deborah Symmons,
Hawys Williams,
Shobna Vasishta,
Rebecca Storey,
Peter Nightingale,
Tags: Full Length Source Type: research
Atorvastatin in the treatment of lithium-induced nephrogenic diabetes insipidus: the protocol of a randomized controlled trial
Lithium is the gold-standard treatment for bipolar disorder, is highly effective in major depressive disorder, and is being investigated for therapeutic benefits in dementia, stroke, and even cancer. Approximately 350,000 Canadians use lithium and more could benefit. Despite this, clinicians are avoiding lithium, largely due to fear of renal toxicity, including irreversible chronic kidney disease (CKD). Nephrogenic Diabetes Insipidus (NDI) occurs in 20% of lithium users and independently predicts a 2-3 times increased risk of CKD.
Source: The American Journal of Geriatric Psychiatry - February 28, 2019 Category: Geriatrics Authors: Jocelyn Fotso Soh, Gabriela Torres-Platas, Serge Beaulieu, Outi Mantere, Robert Platt, Istvan Mucsi, Sybille Saury, Suzane Renaud, Andrea Levinson, Ana Andreazza, Benoit Mulsant, Daniel Mueller, Ayal Schaffer, Annemiek Dols, Nancy Low, Pablo Cervantes, Na Tags: Poster Number: EI - 48 Source Type: research
Fool Me Once: An Uncommon Presentation of PE
BY FREDDIE IRIZARRY-DELGADO; VAROON KAKAIYA; & AHMED RAZIUDDIN, MDAn 86-year-old African-American woman was brought to the ED by her daughter after two days of nutritional neglect, abdominal pain, and altered mental status. Her daughter said her mother felt lightheaded, appeared dehydrated, and vomited nonbilious watery fluid once. The patient had a history of diabetes mellitus type 2, DVT/PE, dementia, and early signs of parkinsonism.Her vital signs were remarkable only for tachypnea (24 bpm). Her troponin I was markedly elevated at 1.7 ng/mL. A D-dimer was ordered because of her history of unprovoked DVT/PE, and i...
Source: The Case Files - November 27, 2018 Category: Emergency Medicine Tags: Blog Posts Source Type: research
Dyslipidemia management in patients with high cardiovascular risk in Spain. ALMA study.
CONCLUSIONS: Although CVR assessment is generally accepted, there is broad disagreement in defining the objectives of LDL-C. Most often than PCPs, the SCPs consider more ambitious targets for LDL-C and the association of lipid-lowering drugs.
PMID: 28619533 [PubMed - as supplied by publisher]
Source: Atencion Primaria - June 12, 2017 Category: Primary Care Authors: Pintó X, Trias Vilagut F, Rius Taruella J, Mairal Sallán E Tags: Aten Primaria Source Type: research
Lipoprotein(a) concentrations, apolipoprotein(a) isoforms and clinical endpoints in haemodialysis patients with type 2 diabetes mellitus: results from the 4D Study
Conclusions
High Lp(a) concentrations and LMW apo(a) isoforms are risk predictors for all-cause mortality and death due to infection in haemodialysis patients with diabetes mellitus. These associations are modified by age.
Source: Nephrology Dialysis Transplantation - November 1, 2016 Category: Urology & Nephrology Authors: Kollerits, B., Drechsler, C., Krane, V., Lamina, C., März, W., Dieplinger, H., Ritz, E., Wanner, C., Kronenberg, F., for the German Diabetes and Dialysis Study Investigators Tags: Chronic Kidney Disease Source Type: research
Edaravone offers neuroprotection for acute diabetic stroke patients
ConclusionEdaravone represents a promising neuroprotectant against cerebral ischemic injury in diabetic patients.
Source: Irish Journal of Medical Science - October 31, 2016 Category: Journals (General) Source Type: research
Statins are 'safe, effective and should be used more widely'
Conclusion
This study reviews evidence from randomised controlled trials (RCTs) and observational studies to better evaluate the effects and safety of statin therapy.
It provides valuable data on the size of the benefits compared with the risks, informing a topic that has had much media coverage in recent times.
The researchers highlight that the benefits of statin therapy for people at risk of cardiovascular disease events far outweigh any possible side effects.
But it is still for a doctor and their patient to come to a conclusion about what the best treatment for them may be.
If you have been prescribed a statin, it...
Source: NHS News Feed - September 9, 2016 Category: Consumer Health News Tags: QA articles Medication Heart/lungs Source Type: news
Interpretation of the evidence for the efficacy and safety of statin therapy
Publication date: Available online 8 September 2016 Source:The Lancet Author(s): Rory Collins, Christina Reith, Jonathan Emberson, Jane Armitage, Colin Baigent, Lisa Blackwell, Roger Blumenthal, John Danesh, George Davey Smith, David DeMets, Stephen Evans, Malcolm Law, Stephen MacMahon, Seth Martin, Bruce Neal, Neil Poulter, David Preiss, Paul Ridker, Ian Roberts, Anthony Rodgers, Peter Sandercock, Kenneth Schulz, Peter Sever, John Simes, Liam Smeeth, Nicholas Wald, Salim Yusuf, Richard Peto This Review is intended to help clinicians, patients, and the public make informed decisions about statin therapy for the prevention...
Source: The Lancet - September 8, 2016 Category: Journals (General) Source Type: research
